Aging-US: Characterization of LncRNA SNHG22 as a protector of NKIRAS2
11-10-2020Aging-US recently published "Characterization of LncRNA SNHG22 as a protector of NKIRAS2 through miR-4492 binding in osteosarcoma\” which reported that the underlying mechanism of SNHG22 in regulating OS progression remains unknown.
In this study, the authors confirmed that SNHG22 was downregulated in OS, and the overexpression of SNHG22 significantly inhibited OS progression in vivo and in vitro.
Meanwhile, overexpression of SNHG22 also inhibited the migration and proliferation of human umbilical vein endothelial cells and prevented the epithelial-to-mesenchymal transition in OS.
Furthermore, the interaction between miR-4492 and SNHG22 they previously predicted was validated by RNA pull-down assays and RNA immunoprecipitation assays.
Dual-luciferase reporter assays showed that SNHG22 could directly interact with miR-4492 and upregulate the expression of NK-κB inhibitor-interacting Ras-like 2 by its competing endogenous RNA activity on miR-4492.
The Aging-US study has clarified the function of SNHG22 in OS progression and suggests a novel therapeutic target for OS.
"The Aging-US study has clarified the function of SNHG22 in OS progression and suggests a novel therapeutic target for OS"
Dr. Sheng-Dan Jiang and Dr. Lei-Sheng Jiang both from The Department of Clinic of Spine Center at Xinhua Hospital said, "Osteosarcoma (OS) is one of the most common primary malignant bone cancers in patients, which presents with two incidence peaks before older adulthood and frequently occurs in long bones such as distal femur and proximal tibia."
Therefore, it is important and urgent to develop new therapeutic targets for OS patients.
Recently, small nucleolar RNA host genes have become a focus of LncRNA research as potential therapeutic targets of cancer.
Figure 8. SNHG22 inhibited tumor growth in vivo. (A) HOS cells transfected with PLKO.1-VECTOR, PLKO.1-SNHG22, PLVX-VECTOR or PLVX-SNHG22 were inoculated into nude mice (n=5). The tumors were excised 3 weeks later. (B) Tumors from different groups were weighed. **P<0.01. (C) Tumor volumes were estimated (0.5 × width2 × length) by caliper every week. **P<0.01. (D) Proteins were extracted from tumors and the expression level of NKIRAS2 and PCNA was measured by western blot. (E) Schematic illustration of the role of SNHG22 in OS cells.
In this study, they investigated the impact of SNHG22 on OS and studied the underlying mechanisms. They found that SNHG22 was downregulated in lung metastatic sites compared with orthotopic OS.
Meanwhile, the authors revealed that SNHG22 could not only inhibited OS cell proliferation, migration and invasion, but also induced cell cycle arrest in vivo by sponging miR-4492 and acting as a competing endogenous RNA for NK-κB inhibitor-interacting Ras-like 2.
The research thus indicated that SNHG22 may be a promising therapeutic target in OS.
The Jiang/Jiang Research Team concluded in their Aging-US Research Paper, "we showed that SNHG22 was downregulated in OS compared with lung metastatic sites. We further found that SNHG22 induced cell cycle arrest in the G1 phase and inhibited the proliferation, migration and invasion of OS cells in vivo. This effect occurred mainly through the interaction with miR-4492, which subsequently targeted the transcription of NKIRAS2. SNHG22 also suppressed EMT in OS. In addition, SNHG22 inhibited the migration and proliferation of HUVECs, while SNHG22 silencing showed the opposite effect. Our study has thus demonstrated that SNHG22 was a pivotal regulator of OS and suggested that SNHG22 may be a novel target for treatment of OS."
Full Text - https://doi.org/10.18632/aging.103849
Correspondence to: Sheng-Dan Jiang email: jiangshengdan@xinhuamed.com.cn and Lei-Sheng Jiang email: jiangleisheng@xinhuamed.com.cn
Keywords: OS, SNHG22, miR-4492, NKIRAS2
About Aging-US:
Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.
Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
Please visit our website at www.Aging-US.com and connect with us:
- X
- YouTube
- Spotify, Apple, SoundCloud, and available wherever you listen to podcasts
For media inquiries, please contact media@impactjournals.com.